Navigation Links
Drug developed by Hebrew U. and others holds promise for treatment of wounds
Date:2/16/2011

Jerusalem, February 7, 2011 -- A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

Diabetes is a rapidly growing medical problem affecting close to 3 percent of the world's population. Poor blood circulation arising from diabetes often results in skin wounds which do not heal, causing pain, infection and at times amputation of limbs.

Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they do not last long on the injured site.

Now, scientists at the Hebrew University and Harvard involved in the project have used genetic engineering to produce a "robotic" growth factor protein that responds to temperature. Increasing the temperature causes dozens of these proteins to fold together into a nanoparticle that is more than 200 times smaller than a single hair.

This behavior greatly simplifies protein purification, making it very inexpensive to produce. It also enables the growth factor to be confined and to remain at the burn or wound site. The scientists refer to their discovery as robotic, since just as robots are machines that respond to their environment by carrying out a specific activity, so too this protein they have developed responds and reacts to heat.

The experimental drug, which ha been developed by the research group as a topical ointment, has been patented and thus far has been used to treat chronic wounds in diabetic mice, dramatically increasing the healing rate. The goal is to proceed to human clinical trials at some future date after future tests and refinements.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Page: 1

Related biology technology :

1. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
2. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
3. Designer molecules being developed to fight disease
4. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
5. New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
6. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
7. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
8. New lab-on-a-chip technique developed at U of T
9. New nanotech sensor developed with medical, chemistry applications
10. New Program Developed in the Fight Against Feline Aids
11. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug developed by Hebrew U. and others holds promise for treatment of wounds
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):